Given the heterogeneity of patients with type 2 diabetes, it is likely that certain subgroups of patients may show better responses to SGLT2 inhibitors than to DPP‐4 inhibitors; such information may help clinicians determine which class of drug might be more suitable for specific patients. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.